BLSH
Bullish
BLSH's outlook is improving, though it still trails on the overall score.
MSFT
Microsoft Corporation
MSFT has the edge over BLSH overall, supported by stronger fundamentals and lower modeled downside.
BLSH Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Stable | |
| Under pressure |
BLSH's cash flow is currently stable, but its revenue, profitability and balance sheet are under pressure.
MSFT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Healthy | |
| Strong |
MSFT's revenue, profitability, cash flow and balance sheet are all currently healthy.
BLSH PE Valuation
BLSH has no meaningful PE right now: it lost money over the past year.
MSFT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $523 | — |
| Cheap | 27x | $525 | +0.4% |
| Current | 27x | $523 | — |
| Fair | 34x | $652 | +25% |
| Expensive | 37x | $711 | +36% |
Historical ranges are pointers, not guarantees.
MSFT's PE is in its cheap range at 27x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
BLSH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BLSH has the edge over MSFT on the outlook, with more favorable profitability expectations.
MSFT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Stable | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for MSFT, with profitability holding steady.
BLSH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.82 | — |
| Q2 2026 | -$9.12 | -$8.12 |
| Q1 2026 | -$6.60 | -$4.07 |
| Q4 2025 | -$5.10 | -1062% |
BLSH lost $9.12 per share over the past year, and its loss has widened in each of the last three quarters.
MSFT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $20.79 | +8.6% |
| Q3 2026 | $19.15 | +36% |
| Q2 2026 | $17.95 | +32% |
| Q1 2026 | $16.80 | +30% |
| Q4 2025 | $15.99 | +29% |
| Q3 2025 | $14.06 | +16% |
| Q2 2025 | $13.64 | +16% |
| Q1 2025 | $12.93 | +12% |
| Q4 2024 | $12.41 | +12% |
MSFT has the edge over BLSH in the latest year-over-year earnings comparison.
BLSH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $92.6M | -100% |
| Q1 2026 | $51.8B | -35% |
| Q4 2025 | $64.4B | -2.5% |
| Q3 2025 | $41.6B | -23% |
| Q2 2025 | $58.7B | +18% |
| Q1 2025 | $80.3B | -0.2% |
BLSH's revenue has slid since its 2024 peak: $93M last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 6.6% | +6.6 points |
| Q1 2026 | -0.1% | -0.1 points |
| Q4 2025 | 0% | 0 points |
| Q3 2025 | 0.1% | +0.1 points |
| Q2 2025 | 0% | 0 points |
| Q1 2025 | 0% | 0 points |
| Q4 2024 | 0% | N/A |
| Q3 2024 | 0% | N/A |
BLSH's operating margin was 6.6% last quarter, up 6.6 points from the same quarter a year ago, near the top of its range since 2024.
MSFT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $92.3B | +19% |
| Q2 2026 | $90B | +18% |
| Q1 2026 | $82.9B | +18% |
| Q4 2025 | $81.3B | +17% |
| Q3 2025 | $77.7B | +18% |
| Q2 2025 | $76.4B | +18% |
| Q1 2025 | $70.1B | +13% |
| Q4 2024 | $69.6B | +12% |
MSFT has the edge over BLSH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 50% | +0.9 points |
| Q2 2026 | 45% | +0.2 points |
| Q1 2026 | 46% | +0.7 points |
| Q4 2025 | 47% | +1.6 points |
| Q3 2025 | 49% | +2.3 points |
| Q2 2025 | 45% | +1.8 points |
| Q1 2025 | 46% | +1.1 points |
| Q4 2024 | 45% | +1.9 points |
MSFT has the edge over BLSH on profitability, with a higher operating margin.
BLSH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.1M | -88% |
| Q1 2026 | $89.6M | +$134.9M |
| Q4 2025 | $54.1M | +52% |
| Q3 2025 | -$48.7M | -$38.8M |
| Q2 2025 | $16.8M | +25% |
| Q1 2025 | -$45.3M | +$27.4M |
BLSH has the edge over MSFT on cash flow, with more consistent year-over-year improvement.
MSFT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $18.6B | -27% |
| Q2 2026 | $19.6B | -23% |
| Q1 2026 | $15.8B | -22% |
| Q4 2025 | $5.9B | -9.3% |
| Q3 2025 | $25.7B | +33% |
| Q2 2025 | $25.6B | +9.6% |
| Q1 2025 | $20.3B | -3.2% |
| Q4 2024 | $6.5B | -29% |
MSFT's free cash flow has been positive every quarter for seven years: $60B over the past year, down 23% from the year before.
BLSH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +270K shares |
| 1 year | +3.6% | +5.2M shares |
BLSH has 151M diluted shares, up 3.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BLSH hasn't bought back shares in the past year.
MSFT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -7M shares |
| 1 year | -0.3% | -20M shares |
| 3 years | -0.2% | -16M shares |
| 5 years | -1.6% | -121M shares |
| Available history | -3.2% | -245M shares |
MSFT has the edge over BLSH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.4B |
| Q2 2026 | $4.6B |
| Q1 2026 | $4.6B |
| Q4 2025 | $7.4B |
| Q3 2025 | $5.7B |
| Q2 2025 | $4.5B |
| Q1 2025 | $4.8B |
| Q4 2024 | $5B |
MSFT spent $21B buying back its own shares over the past year, up 5.2% from the year before.
BLSH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | 3.9x | Elevated |
BLSH's net debt is about 3.9 years of its operating earnings (EBITDA).
MSFT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.1x | Very low |
MSFT's net debt is less than a year of its operating earnings (EBITDA).
BLSH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.1 | Neutral |
| Stochastic | 12.1 | Oversold |
BLSH's weekly RSI is 39 (neutral) and its Stochastic is 12 (oversold).
MSFT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.1 | Neutral |
| Stochastic | 68.0 | Neutral |
MSFT's weekly RSI is 62 (neutral) and its Stochastic is 68 (neutral).
BLSH PE vs Technology Sector
BLSH has no meaningful PE right now: it lost money over the past year.
MSFT PE vs Technology Sector
| Metric | MSFT | Sector median | Relative |
|---|---|---|---|
| PE | 27x | 28x | 2% below |
| PE % | 16 | 35 | 19 pts below |
MSFT is trading at 27x earnings, in line with the Technology sector's median of 28x.
BLSH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 20% below |
| 20 week MA | $28.5 | 19% below |
| 50 week MA | $32.8 | 29% below |
MSFT has stronger trend alignment. BLSH is above 0 of 3 weekly averages versus MSFT above 4 of 5.
MSFT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $524.7 | 0.3% below |
| 20 week MA | $484.8 | 7.9% above |
| 50 week MA | $446.9 | 17% above |
| 100 week MA | $453.8 | 15% above |
| 200 week MA | $411.5 | 27% above |
MSFT's trend is up, with a small recent dip: it's below only its 8-week average, and 27% above its 200-week average.
BLSH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $69.5 | $41.1 | -41% |
| 2026 YTD | $41.1 | $23.2 | -44% |
BLSH has finished every year since 2025 lower, and it's down 44% so far in 2026.
MSFT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $159.0 | $222.8 | +40% |
| 2021 | $222.8 | $334.7 | +50% |
| 2022 | $334.7 | $238.7 | -29% |
| 2023 | $238.7 | $376.0 | +58% |
| 2024 | $376.0 | $430.5 | +14% |
| 2025 | $430.5 | $487.7 | +13% |
| 2026 YTD | $487.7 | $523.0 | +7.2% |
MSFT has the edge over BLSH on returns for 2026, with the stronger performance.